The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus
placebo in adult subjects with systemic lupus erythematosus (SLE).
This is a Phase 2b, multicenter, multinational, randomized, double-blind, placebo-controlled
study to evaluate the efficacy and safety of 4 doses of cenerimod versus placebo in adult
subjects with moderately to severely active, autoantibody-positive systemic lupus
Approximately 500 adult subjects with SLE will be randomized in a 1:1:1:1:1 ratio to placebo,
0.5, 1, 2, or 4 mg o.d. of cenerimod, in addition to background SLE therapy.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.